Answers are grounded in this paper and cite their sources.
Current ERBB2 status may be more effective than archival status at predicting clinical benefit from margetuximab plus pembrolizumab therapy. ctDNA testing for ERBB2 status prior to treatment will spare patients from repeat tissue biopsies, which may be reserved for reflex testing when ctDNA is not detected.
No takes yet. Share an insight, caveat, or question.
Daniel V.T. Catenacci (2023) studied this question.